BeiGene has agreed to sell global ex-China royalty rights for Amgen's CD3/DLL3 bispecific antibody (BsAb) Imdelltra (tarlatamab) to Royalty Pharma for up to USD 950 million, including USD 885 million upfront. The deal allows BeiGene to monetise its 2020 licensing agreement with Amgen while retaining rights to other partnered assets like STEAP1/CD3 bispecific xaluritamig. Imdelltra, approved in the US in 2024 for small cell lung cancer (SCLC), demonstrated 40% response rates and 14.3-month median survival in Phase II trials.

BeiGene maintains full China rights to Imdelltra, which is under regulatory review for second-line SCLC domestically. The company continues co-developing five Amgen pipeline candidates, including Phase III-ready xaluritamig for prostate cancer. The transaction highlights BeiGene's strategic shift toward prioritising proprietary oncology assets.

PharmCube's NextBiopharm® database shows that Imdelltra is undergoing 53 clinical trials globally. Click here to request a free trial for NextBiopharm®.